31910 Federal Register / Vol. 87, No. 101 / Wednesday, May 25, 2022 / Notices 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. All 

requests for a hearing must be sent to: 

(1) Drug Enforcement Administration, 

Attn: Hearing Clerk/OALJ, 8701 

Morrissette Drive, Springfield, Virginia 

22152; and (2) Drug Enforcement 

Administration, Attn: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing should 

also be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on March 24, 2022, United 

States Pharmacopeial Convention, 7135 

English Muffin Way, Frederick, 

Maryland 21704, applied to be 

registered as an importer of the 

following basic class(es) of controlled 

substance(s): 

Controlled substance Drug code Schedule 

Cathinone ........................................................................................................................................................................ 1235 I 

Methcathinone ................................................................................................................................................................. 1237 I 

Methaqualone .................................................................................................................................................................. 2565 I 

Lysergic acid diethylamide .............................................................................................................................................. 7315 I 

4-Methyl-2,5-dimethoxyamphetamine ............................................................................................................................. 7395 I 

3,4-Methylenedioxyamphetamine .................................................................................................................................... 7400 I 

4-Methoxyamphetamine .................................................................................................................................................. 7411 I 

Codeine-N-oxide .............................................................................................................................................................. 9053 I 

Difenoxin .......................................................................................................................................................................... 9168 I 

Heroin .............................................................................................................................................................................. 9200 I 

Morphine-N-oxide ............................................................................................................................................................ 9307 I 

Norlevorphanol ................................................................................................................................................................ 9634 I 

Methamphetamine ........................................................................................................................................................... 1105 II 

Lisdexamfetamine ............................................................................................................................................................ 1205 II 

Phenmetrazine ................................................................................................................................................................. 1631 II 

Methylphenidate .............................................................................................................................................................. 1724 II 

Amobarbital ...................................................................................................................................................................... 2125 II 

Pentobarbital .................................................................................................................................................................... 2270 II 

Secobarbital ..................................................................................................................................................................... 2315 II 

Glutethimide ..................................................................................................................................................................... 2550 II 

Phencyclidine ................................................................................................................................................................... 7471 II 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ..................................................................................................................... 8333 II 

Phenylacetone ................................................................................................................................................................. 8501 II 

Alphaprodine .................................................................................................................................................................... 9010 II 

Anileridine ........................................................................................................................................................................ 9020 II 

Cocaine ............................................................................................................................................................................ 9041 II 

Dihydrocodeine ................................................................................................................................................................ 9120 II 

Diphenoxylate .................................................................................................................................................................. 9170 II 

Levomethorphan .............................................................................................................................................................. 9210 II 

Levorphanol ..................................................................................................................................................................... 9220 II 

Meperidine ....................................................................................................................................................................... 9230 II 

Dextropropoxyphene, bulk (non-dosage forms) .............................................................................................................. 9273 II 

Thebaine .......................................................................................................................................................................... 9333 II 

Oxymorphone .................................................................................................................................................................. 9652 II 

Noroxymorphone ............................................................................................................................................................. 9668 II 

Alfentanil .......................................................................................................................................................................... 9737 II 

Sufentanil ......................................................................................................................................................................... 9740 II 

The company plans to import the bulk 

control substances for distribution as 

analytical reference standards to its 

customers for analytical testing of raw 

materials. No other activities for these 

drug codes are authorized for this 

registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

Kristi N. O’Malley, 

Assistant Administrator. 

[FR Doc. 2022–11263 Filed 5–24–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1023] 

Importer of Controlled Substances 

Application: Curia New York Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Curia New York Inc. has 

applied to be registered as an importer 

of basic class(es) of controlled 

substance(s). Refer to SUPPLEMENTARY

INFORMATION listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before June 24, 2022. Such 

persons may also file a written request 

for a hearing on the application on or 

before June 24, 2022. 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 101 / Wednesday, May 25, 2022 / Notices 31911 

ADDRESSES: The Drug Enforcement 

Administration requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. All 

requests for a hearing must be sent to: 

(1) Drug Enforcement Administration, 

Attn: Hearing Clerk/OALJ, 8701 

Morrissette Drive, Springfield, Virginia 

22152; and (2) Drug Enforcement 

Administration, Attn: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing should 

also be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on February 23, 2022, 

Curia New York Inc., 33 Riverside 

Avenue, Rensselaer, New York 12144, 

applied to be registered as an importer 

of the following basic class(es) of 

controlled substance(s): 

Controlled substance Drug 

code Schedule 

ANPP (4-Anilino-Nphenethyl-4-piperidine).8333 II 

The company plans to import the 

listed controlled substance for 

distribution to its customers. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

Kristi N. O’Malley, 

Assistant Administrator. 

[FR Doc. 2022–11268 Filed 5–24–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1002] 

Bulk Manufacturer of Controlled 

Substances Application: Invizyne 

Technologies, Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Invizyne Technologies, Inc. 

has applied to be registered as a bulk 

manufacturer of basic class(es) of 

controlled substance(s). Refer to 

SUPPLEMENTARY INFORMATION listed 

below for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before July 25, 2022. Such persons 

may also file a written request for a 

hearing on the application on or before 

July 25, 2022. 

ADDRESSES: The Drug Enforcement 

Administration requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on March 14, 2022, 

Invizyne Technologies, Inc., 750 Royal 

Oaks Drive, Suite 106, Monrovia, 

California 91016–6357, applied to be 

registered as a bulk manufacturer of the 

following basic class(es) of controlled 

substance(s): 

Controlled substance Drug 

code Schedule 

Tetrahydrocannabinols .... 7370 I 

The company plans to bulk 

manufacture the listed controlled 

substance for the internal use 

intermediates or for sale to its 

customers. In reference to drug code 

7370 (Tetrahydrocannabinols), the 

company plans to bulk manufacture this 

drug as synthetic. No other activities for 

this drug code is authorized for this 

registration. 

Kristi N. O’Malley, 

Assistant Administrator. 

[FR Doc. 2022–11252 Filed 5–24–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

[OMB Number1122–0023] 

Agency Information Collection 

Activities; Proposed eCollection 

eComments Requested; Extension of a 

Currently Approved Collection 

AGENCY: Office on Violence Against 

Women, Department of Justice. 

ACTION: 60-Day notice. 

SUMMARY: The Department of Justice, 

Office on Violence Against Women 

(OVW) will be submitting the following 

information collection request to the 

Office of Management and Budget 

(OMB) for review and approval in 

accordance with the Paperwork 

Reduction Act of 1995. 

DATES: Comments are encouraged and 

will be accepted for 60 days until July 

25, 2022. 

FOR FURTHER INFORMATION CONTACT: 

Written comments and/or suggestion 

regarding the items contained in this 

notice, especially the estimated public 

burden and associated response time, 

should be directed to Cathy Poston, 

Office on Violence Against Women, at 

202–514–5430 or Catherine.poston@

usdoj.gov. 

SUPPLEMENTARY INFORMATION: Written 

comments and suggestions from the 

public and affected agencies concerning 

the proposed collection of information 

are encouraged. Your comments should 

address one or more of the following 

four points: 

(1) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(2) Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(3) Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

(4) Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 


lotter on DSK11XQN23PROD with NOTICES1

I I 

I I